Stentys has raised US$18 million
Stentys has raised US$18 million through private equity investment.
Stentys develops a new-generation stent designed for treatment of acute myocardial infarction and coronary artery bifurcations. Based in Princeton, New Jersey, and Paris, France, the company intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure.
Oaklins’ team in France advised Stentys on its two financing rounds, raising a total of US$18 million. The team continues to advise Stentys on corporate strategic matters.
Talk to the deal team
Related deals
Blue Groep has been acquired by Glowi
The owner of Blue Groep has sold the company to Glowi. With this strategic acquisition, Glowi expands its portfolio and capabilities in facility management and staffing solutions to support its ongoing growth.
Learn moreAlcidion has raised capital
Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.
Learn moreA group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
Learn more